Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11879018 | 0.78 | ATAD2 (0.52) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL158784 | 0.71 | — | — | |
| SCHEMBL15798699 | 0.71 | KDM4E (0.41) | KMT2AALDH1A1KDM4E | |
| Uracil SCHEMBL27791187 | 0.67 | CRBN (0.57) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL28113870 | 0.64 | KAT2B (0.33) | MEN1KMT2A | |
| SCHEMBL448104 | 0.63 | ATAD2 (0.48) | ATAD2 | |
| SCHEMBL22146244 | 0.59 | JAK2 (0.37) | — | |
| SCHEMBL10579911 | 0.58 | AURKA (0.33) | PDPK1 | |
| SCHEMBL2490716 | 0.58 | ADORA2A (0.38) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL12715779 | 0.58 | PDPK1 (0.53) | ALDH1A1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195003-B | Drug delivery system using solution | 国立大学法人京都大学 | 2024-12-31 | — | — | CN | disclosed |
| US-20220023207-A1 | DRUG DELIVERY SYSTEM USING SOLUTION | KYOTO UNIVERSITY (JP) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023207-A1 | DRUG DELIVERY SYSTEM USING SOLUTION | PDIA6, PDIA5, DUS2 | MEN1 942/4885KMT2A 4411/4885LMNA 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.